Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 + Docetaxel in Advanced Urothelial Carcinoma
NCT01907308Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of trebananib in urothelial carcinoma (UC), sponsored by University of Colorado Denver. Planned start Feb 2014; status: withdrawn.
02
Drugs
trebananib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01907308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01907308.